Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab

Abstract

Objective: To investigate resource use and time investments of healthcare professionals, patients and their family and to compare healthcare and societal costs of one single hospital-based and one single home-based subcutaneous administration of trastuzumab in The Netherlands. Method: We conducted a bottom-up micro-costing study. Patients diagnosed with HER2þ early or metastatic breast cancer were recruited in four Dutch hospitals. For healthcare costs, data were collected on drug use, consumables, use of healthcare facilities, time of healthcare professionals, and travelling distance of the nurse. For societal costs, data were collected on patient and family costs (including travelling expenses and time of informal caregivers) and productivity losses of paid and unpaid work. Results: Societal costs of one single administration of SC trastuzumab were V1753 within the homebased and V1724 within the hospital-based setting. Drug costs of trastuzumab were identical in both settings (V1651). Healthcare costs were higher for home-based administration (V91 versus V47) mainly because of more time of healthcare professionals (110 versus 38 minutes). Costs for patient and family were, however, lower for home-based administration due to travelling expenses (V7 versus V0) and time of informal caregivers (V14 versus V4). Costs for productivity losses were similar for both settings. Conclusions: Home-based subcutaneous administration of trastuzumab is more time consuming for healthcare professionals and therefore more costly than hospital-based administration. The total budget impact can be large considering that a large number of patients receive a large number of cycles of oncology treatments. If home-based administration is the way forward, novel approaches are crucial for ensuring efficiency of home-based care.

Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands

“…First, a lack of data on the number of at-home infusions and their associated costs meant that at-home administration was not implemented in our model. A Dutch study comparing at-home and in-hospital administration of trastuzumab showed that the costs are comparable overall for the two settings [ 51 ]. Although the healthcare-related costs of at-home administration were higher compared with in-hospital administration, societal costs were lower due to reduced patient travel costs and productivity losses.…”

Home Cancer Care Research: A Bibliometric and Visualization Analysis (1990–2021)

“…A growing number of studies are evaluating home chemotherapy as an alternative to hospitalization, especially for pediatric cancer patients. Studies focused on different outcomes, such as cost [ 84 , 85 ], adherence [ 86 ], safety [ 87 ], compliance, satisfaction, and quality of life [ 76 ].…”

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands

“…Further, productivity losses for unpaid work on part of the patient and of their informal caregiver during the friction cost period ( 40 ) were included. Such losses were assumed to be linked to first- and second-line treatment administrations ( 46 ). The costs were based on hourly proxy costs for cleaning labor in the Netherlands ( 40 ).…”